Aravive (delisted) (VSAR) News

ARAV - Aravive Inc. is the new stock for this.

delisted?

Aravive FDA fast track designation pr

Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

http://aravive.com/press-releases/u-s-fda-grants-fast-track-designation-to-aravive-biologics-avb-s6-500/

VSAR merger partner Aravive receives FDA fast track designation, not pr'd yet

plus new filing Baker Brothers added 1 million shares of $VSAR, a 70% increase from previous position. Now a 6.7% ownership.

http://ir.versartis.com/news-releases/news-release-details/versartis-enters-merger-agreement-aravive-biologics-form

VSAR I'm game @ $1.83

Why are they buying? Any new products on the pipeline? Does VSAR have potential for the short term?

More insider buying this week! www.edgarpulse.com/form4-insider-summary.php?form4=2650257 $3++ coming next week.

Gapping big Monday. $$$

Great close today. In at 2.10

I think someone bought it finally??? Is that the news for today? I can see green soon finally too maybe. LOL

* * $VSAR Video Chart 06-08-18 * *

Link to Video - click here to watch the technical chart video

I agree cancer treatment is huge and it’s sad but more and more people are getting cancer everyday a lot to do with our lifestyles... IMO THIS WILL BE HUGE ANYTHING UNDER 2.00 sounds cheap to me.

IMO THIS COULD GO TO 3 to 5 DOLLARS EASY .... IM LOADING THIS ONE !!!!

VSAR WOW MERGER AND CANCER TREATMENT... I’m a nurse and this imo is HUGE ...UNDERVALUED $$$

VSAR maybe will run up and close near 2.00 $$$$

now 277M bids ...somebodies loaded it BIG @ 1.45, lets see if can climb back to 1.60


where I bought it

l;ol

above $2 if I remember well

Director bought shares $2M.

what price?

Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics


http://aravive.com/pipeline/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141272944

Grabbed 60 $2 calls- gambling here

I am extremely confused but hopefully I am wrong about your opinion. In the corporate update, each one of the bullet points explain why the drug is dead in the water. The last bullet point clearly innuendos that they are either going to rm or purchase an asset to develop.

Can you please do me a huge favor and dissect the bullet points below and explain how you pull any possible way that you see a way forward for their hgh drug??? Further more I cannot imagine Teijin releasing their interest if there was any way possible for a future. Please advise.

Corporate Update

Based on a full review of the data from the Phase 3 VELOCITY trial, feedback from the FDA during the development of somavaratan, and an objective assessment by external regulatory experts, the company believes it could not successfully file for approval based on the existing dataset.
All current clinical trials of somavaratan have been concluded and the U.S. Investigational New Drug Application (IND) and equivalent filings in other countries have been withdrawn. Additionally, in January 2018, Teijin Limited (Teijin) terminated its license agreement for somavaratan in Japan following its evaluation of the VELOCITY trial results.
The investment and delay in time-to-market that further development would require significantly impact the business case for somavaratan, given the potential that one or more long-acting growth hormone products may already be commercialized for pediatric growth hormone deficiency during that time.
The company is focused on evaluating strategic opportunities to leverage its expertise and resources to create value for shareholders. Cowen is assisting the company in reviewing possible transactions, including strategic combinations and opportunities to diversify the Versartis pipeline.

Of course there is a possibility of reverse takeover, too. But with all the progress have been made so far as described under the Corporate Update session in the E/R which can be viewed via this link ), and we all know that Versartis's Somavaratan does work (as described in this article ), it's just that the drug is as effective as Pfizer's Genotropin, but Somavaratan is designed for bi-weekly treatment while Pfizer's Genotropin required daily injection, and Ascendis's TransCon designed for weekly treatment, and also Somavaratan can be stored at room temperature. Given all of this, what would be best scenario for maximizing shareholders value? THX!

What, acquire the entire company? Why? Don't you think a reverse merger likelier, or an attempt to buy just the compound, not the company?

The following text is from today earning release:

... said Jay Shepard, President and CEO of Versartis, Inc. “While we cannot make any assurances that a strategic transaction will be recommended by the Board, we are encouraged by the interest and opportunities we have seen and we are now at an advanced stage in our review process. Our goal remains to maximize value for all Versartis shareholders. We sincerely appreciate the patience shareholders have shown as we evaluate paths forward and we hope to provide a further update in the coming weeks.”

The texts in bold & underline clearly indicate that they're near the conclusion of the reviewing process and the decision will be announced very soon in the next couple weeks.

And the balance sheet from the latest earning report:
- Total assets: $93.78M
- Total liabilities: $11.02M
- Total stockholders' equity = $93.78M - $11.02M = $82.76M
- Total # of outstanding shares = $31.1M/$0.87 = 35.75M shares

So for the worst case scenario: company properties to be auctioned and cash distributed back to shareholders, we will receive at least $82.76M/35.75M = $2.31/share. I think the possibility for this occurred is very small and someone will pay at least $8/share to acquire VSAR.

So far 158K shares traded as high as $1.80 after the hours:
https://www.nasdaq.com/symbol/vsar/after-hours

Yes, %100 agree with you on this; we're sitting on a gold mine.

Add in proprietary assets and we’re @ $4-$5

Q4 2017 E/R just came out; up by 12.58% after the hour and will trade above $2 tomorrow as the existing amount of cash after all liabilities is currently at: $49.24M + $31.1M = $80.34M. With # outstanding shares @ 35.81M share, cash/share = $80.34/35.81 = $2.24/share

https://finance.yahoo.com/news/versartis-reports-fourth-quarter-full-210500107.html
For the fourth quarter ended December 31, 2017, Versartis reported a net income of approximately $31.1 million, or $0.87 per share, basic and diluted, compared to a net loss for the fourth quarter ended December 31, 2016 of $22.1 million, or $0.64 per share, basic and diluted.

Somebody bought 552k shares in one chunk in the early afternoon. That is a WTF trade if I’ve ever seen one. Come on good news, we’ve been waiting!!!!

from what i understand from the reply. the 'coincident' seems to mean there will be additional info beside the usual stuff that is in a 10k. anyone read the same?

I’m the guy who put it on StockTwits

I emailed him via the website and received this answer back the next day.

Who received that email? Name is xxx out - how did you get it?

I hope it’s good news

Thanks for the inquiry. I have been trying to get an answer from them for weeks. Sounds like we will be getting an update any day now. Hopefully it will be worth all of our time!!!!

Dear Mr. xxxx:

I am in receipt of your below email and prior correspondence. As you may be aware, SEC regulations mandate filing of our 2017 Annual Report on Form 10-K on or before March 16, 2018. In keeping with our historical practice, we intend to provide a corporate update coincident with that filing.

Kind regards,

Shane M. Ward
Senior Vice President and General Counsel

Versartis, Inc.
1020 Marsh Road
Menlo Park, CA 94025
p: 650-433-2639
m: 847-913-6161

My mistake, I just read through their last 50 filings. The company has historically posted their 10K's (not Q's) on March 6th (2015), March 8th (2016), and March 10th (2017). So we *MAY* not see anything here for another week or two (2 weeks from today would be March 9th). I had thought for sure I had seen February 28th but I must have been thinking of a different stock.

Gives people some additional time to accumulate if they anticipate something brewing and want to load up a little more. :)

If their cash burn rate has decreased significantly as I suspect and they are still loaded with cash on hand, then this could be due for a big move from these levels. Chart looks massively oversold.

Good luck to all.

That makes me feel better as a holder lol. Yeah E*TRADE was showing me 2/21 as earnings date so I was confused by the non appearance. Thank you kindly for your response!

Company has historically posted it in the last few days of February, not sure why everyone was insisting it was yesterday or why people are saying it was "supposed to" (aside from some brokerage firms posting the expected date). It should be out sometime next week.

ER was supposed to be yesterday but company no showed

Thanks for sharing your research/thoughts on this one longx. I too am intrigued by what I have found with VSAR and find it curious just how tightly it is trading right now (pinned in this $1.65-$1.75 range). The accumulation is obvious and the chart looks massively oversold IMO, so it makes me wonder what is brewing behind the scenes here. (the insider and institutional purchases are exciting as well). Unless I am missing something, this is trading well under the company's cash value which leads me to believe a big move may be coming.

On heavy watch right now and very interested to see the latest ER next week.

Still havent released Fins after 8pm, too busy packing up bags for first flight out of town?

Quarterly report should be today AH, maybe now we can get some kind of goddamn update.

Read the form, it was required sales to cover tax withholdings.

Big higher ups now selling there shares. Don’t think theyd be selling at 1.80 if good news was coming

I'm actually still in the sideline for VSAR due to cash burn concern. I don't have a narrow estimate range on the burn, but the fact that the company reported over 40 million and over 20 million net losses for the September and June quarters, respectively, are huge % to the cash equity. Market cap is now ~$60 mil. I don't think one can necessarily loss (too much) at this level swing trade it, but I don't find it attractive enough yet without knowing the actual cash burn for the December quarter. I normally do not like to recommend stocks and be part of ones financial loss as I know I can be wrong on my picks too.

Versartis, Inc. is estimated to report earnings on 02/20/2018. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.88. The reported EPS for the same quarter last year was $-0.64.
http://www.nasdaq.com/earnings/report/vsar

With 2/3 workforce reduction and many senior management positions eliminated, I think Q4/17 EPS will be around -$0.15/share

It's a wild Swing in the markets today; that's how the big guys shook out those weak hands.
https://finance.yahoo.com/quote/%5EDJI?p=^DJI

Ahh, didn’t realize that happened then. Thanks.